Vaxxinity (VAXX)
(Delayed Data from OTC)
$0.04 USD
0.00 (5.26%)
Updated Aug 2, 2024 03:56 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
VAXX 0.04 0.00(5.26%)
Will VAXX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for VAXX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for VAXX
The Zacks Analyst Blog Highlights Biogen, Prothena, AC Immune's and Vaxxinity
Alzheimer's Disease Space Evolves in 2023: Stocks in Focus
VAXX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Merck's (MRK) Meets Goal in Muscle-Invasive Bladder Cancer Study
ALX Oncology (ALXO) Up 56% on Upbeat Gastric Cancer Study Data
Sanofi (SNY) Inks Deal With J&J to Develop E. coli Vaccine
Other News for VAXX
Vaxxinity UB-312 Parkinson?s Trial Results Published in Nature Medicine
Vaxxinity's Parkinson's candidate UB-312 demonstrates efficacy in publication